Ubs Group Ag Trevena Inc Transaction History

Ubs Group Ag

  • $452 Billion
  • Q3 2024

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 10, 2022
SELL
$0.16 - $100.0 $5,089 - $3.18 Million
-31,809 Reduced 66.42%
16,081 $2,000
Q2 2022

Aug 10, 2022
BUY
$0.2 - $0.5 $2,455 - $6,139
12,279 Added 34.48%
47,890 $19,000
Q1 2022

May 16, 2022
SELL
$0.41 - $0.63 $19,101 - $29,351
-46,590 Reduced 56.68%
35,611 $19,000
Q4 2021

Feb 14, 2022
BUY
$0.57 - $1.29 $38,304 - $86,689
67,201 Added 448.01%
82,201 $48,000
Q3 2021

Nov 15, 2021
SELL
$1.11 - $1.7 $33,306 - $51,010
-30,006 Reduced 66.67%
15,000 $18,000
Q2 2021

Aug 13, 2021
BUY
$1.46 - $2.25 $24,869 - $38,326
17,034 Added 60.9%
45,006 $76,000
Q1 2021

May 12, 2021
BUY
$1.77 - $2.93 $22,960 - $38,007
12,972 Added 86.48%
27,972 $50,000
Q4 2020

Feb 11, 2021
BUY
$2.13 - $3.26 $31,950 - $48,900
15,000 New
15,000 $32,000
Q3 2020

Nov 12, 2020
SELL
$1.53 - $3.13 $28,756 - $58,828
-18,795 Closed
0 $0
Q2 2020

Jul 31, 2020
BUY
$0.48 - $1.75 $5,870 - $21,404
12,231 Added 186.33%
18,795 $28,000
Q1 2020

May 01, 2020
BUY
$0.56 - $0.97 $2,362 - $4,091
4,218 Added 179.8%
6,564 $4,000
Q4 2019

Feb 14, 2020
SELL
$0.62 - $1.06 $4,745 - $8,113
-7,654 Reduced 76.54%
2,346 $2,000
Q4 2018

Feb 14, 2019
BUY
$0.39 - $3.47 $145 - $1,294
373 Added 3.87%
10,000 $4,000
Q3 2018

Nov 14, 2018
BUY
$1.39 - $2.25 $5,544 - $8,975
3,989 Added 70.75%
9,627 $20,000
Q2 2018

Aug 14, 2018
BUY
$1.44 - $2.24 $918 - $1,429
638 Added 12.76%
5,638 $8,000
Q1 2018

May 15, 2018
BUY
$1.51 - $2.06 $7,550 - $10,300
5,000 New
5,000 $8,000
Q3 2017

Nov 14, 2017
SELL
$2.22 - $2.79 $15,864 - $19,937
-7,146 Closed
0 $0
Q2 2017

Aug 14, 2017
BUY
N/A
6,146 Added 614.6%
7,146 $16,000
Q1 2017

Nov 14, 2017
BUY
N/A
1,000
1,000 $4,000

About TREVENA INC

TRVN Quotes by TradingView
  • Ticker TRVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 173,680,992
  • Market Cap $273M
  • Description
  • Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV...
More about TRVN
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email